[Pulmonary invasive aspergillosis: value of treatment with intravenous amphotericin B administered in a triglyceride emulsion for parenteral usage].
Pulmonary invasive aspergillosis is a frequent and poor prognosis complication of immuno-deficiency and prolonged neutropenia. Its treatment is usually based on amphotericin B (0.7 to 1 mg/kg/d) given as intravenous infusions for at least 2 months. This therapy is limited by the side-effects of the drug including renal failure, myelosuppression, chills and fever. We present here the case of women with pulmonary invasive aspergillosis treated with a different modality of administration. The amphotericin B was given as a continuous infection at 2 mg/kg/d diluted in Intralipid, a triglyceridic mixture used in parenteral nutrition. Given by this way amphotericin B seems to have a good therapeutic efficiency and a mild toxicity limited to transient reduction in creatinine clearance with increased kaliuria. Other current approaches of invasive aspergillosis include the amphotericin B in liposomes, combination of amphotericin B with 5-fluorouracil and the triazolated compounds.
Andrès
E
E
Service d'oncologie médicale, CHU de Strasbourg, 1, place de l'Hôpital, France.
Limacher
J M
JM
Bergerat
J P
JP
D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000188:drug therapy*; D004655:Emulsions; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000503:physiopathology; D008875:Middle Aged; D013997:Time Factors; D014280:Triglycerides / Q000008:administration & dosage
D004655:Emulsions; D014280:Triglycerides; D000666:Amphotericin B
Aspergillose pulmonaire invasive: intérêt d'un traitement par amphotéricine B intraveineuse administrée dans une émulsion triglycéridique à usage parentéral.